Phase 4 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People of any gender
- People aged 15 years or older at the time of signing the consent form
- People who weigh at least 35 kg
- People who have a confirmed HIV-1 diagnosis
- People who have received at least one dose of long-acting cabotegravir (CAB-LA) as HIV prevention (PrEP) in the past 12 months
- People who agree to start HIV treatment (ART)
- People whose kidneys are functioning above a certain level, based on a blood test result (confirm with trial site)
Who may not be able to join:
- People who have previously taken the HIV medication dolutegravir (DTG)
- People who are currently taking part in, or have taken part in within the last 3 months, another clinical trial involving a medication that could interfere with this study
- People who have a known allergy or medical reason to avoid any of the medications used in this trial
- People who are currently taking, or have taken within the past 28 days, certain tuberculosis medications (such as rifampicin, rifapentine, or rifabutin — not including isoniazid prevention therapy), certain anti-seizure medications (such as carbamazepine, oxcarbazepine, phenobarbital, or phenytoin), or herbal products such as St John's Wort — unless those medications can be safely stopped for the duration of the study
- People who have a medical or surgical condition that could significantly affect how medications are absorbed or processed in the body, or that could affect their safety or ability to follow the study schedule (the trial doctor makes this assessment based on medical history)
- People who the trial doctor believes are unlikely to be able to follow the study requirements, or who would be unable or unwilling to attend follow-up visits for the full study period
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: FRANCOIS WD VENTER, PhD, Ezintsha, a division of Wits Health Consortium
Phone: 0110844961
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
To evaluate the efficacy of TLD as first-line antiretroviral therapy (ART) in participants with HIV-1 infection and CAB-LA PrEP exposure in the past 12 months
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.